Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 561

1.

Rosiglitazone, a Ligand to PPARγ, Improves Blood Pressure and Vascular Function through Renin-Angiotensin System Regulation.

Sánchez-Aguilar M, Ibarra-Lara L, Del Valle-Mondragón L, Rubio-Ruiz ME, Aguilar-Navarro AG, Zamorano-Carrillo A, Ramírez-Ortega MDC, Pastelín-Hernández G, Sánchez-Mendoza A.

PPAR Res. 2019 Feb 3;2019:1371758. doi: 10.1155/2019/1371758. eCollection 2019.

2.

6-Gingerol Normalizes the Expression of Biomarkers Related to Hypertension via PPARδ in HUVECs, HEK293, and Differentiated 3T3-L1 Cells.

Lee YJ, Jang YN, Han YM, Kim HM, Seo HS.

PPAR Res. 2018 Dec 16;2018:6485064. doi: 10.1155/2018/6485064. eCollection 2018.

3.

Crosstalk between MicroRNAs and Peroxisome Proliferator-Activated Receptors and Their Emerging Regulatory Roles in Cardiovascular Pathophysiology.

Zhang YF, Xu HM, Yu F, Wang M, Li MY, Xu T, Gao YY, Wang JX, Li PF.

PPAR Res. 2018 Dec 5;2018:8530371. doi: 10.1155/2018/8530371. eCollection 2018. Review.

4.

Erratum to "Inducible Conditional Vascular-Specific Overexpression of Peroxisome Proliferator-Activated Receptor Beta/Delta Leads to Rapid Cardiac Hypertrophy".

Wagner KD, Vukolic A, Baudouy D, Michiels JF, Wagner N.

PPAR Res. 2018 Oct 29;2018:5480829. doi: 10.1155/2018/5480829. eCollection 2018.

5.

Signaling Mechanisms of Selective PPARγ Modulators in Alzheimer's Disease.

Govindarajulu M, Pinky PD, Bloemer J, Ghanei N, Suppiramaniam V, Amin R.

PPAR Res. 2018 Oct 21;2018:2010675. doi: 10.1155/2018/2010675. eCollection 2018. Review.

6.

Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression.

Ahn HY, Kim HH, Hwang JY, Park C, Cho BY, Park YJ.

PPAR Res. 2018 Sep 27;2018:9568269. doi: 10.1155/2018/9568269. eCollection 2018.

7.

A Reduction in ADAM17 Expression Is Involved in the Protective Effect of the PPAR-α Activator Fenofibrate on Pressure Overload-Induced Cardiac Hypertrophy.

Zeng SY, Lu HQ, Yan QJ, Zou J.

PPAR Res. 2018 Jul 19;2018:7916953. doi: 10.1155/2018/7916953. eCollection 2018.

8.

Combined Rosiglitazone and Forskolin Have Neuroprotective Effects in SD Rats after Spinal Cord Injury.

Meng QQ, Lei W, Chen H, Feng ZC, Hu LQ, Zhang XL, Li S.

PPAR Res. 2018 Jun 21;2018:3897478. doi: 10.1155/2018/3897478. eCollection 2018.

9.

Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice.

Choung S, Joung KH, You BR, Park SK, Kim HJ, Ku BJ.

PPAR Res. 2018 Jun 13;2018:4292509. doi: 10.1155/2018/4292509. eCollection 2018.

10.

Expression of GPR43 in Brown Adipogenesis Is Enhanced by Rosiglitazone and Controlled by PPARγ/RXR Heterodimerization.

Hu J, Zhou A, Cheung PCK, Zheng B, Zeng S, Lin S.

PPAR Res. 2018 May 16;2018:1051074. doi: 10.1155/2018/1051074. eCollection 2018.

11.

Inhibitory Effects of a Novel PPAR-γ Agonist MEKT1 on Pomc Expression/ACTH Secretion in AtT20 Cells.

Parvin R, Noro E, Saito-Hakoda A, Shimada H, Suzuki S, Shimizu K, Miyachi H, Yokoyama A, Sugawara A.

PPAR Res. 2018 Apr 23;2018:5346272. doi: 10.1155/2018/5346272. eCollection 2018.

12.

Cellular and Biophysical Pipeline for the Screening of Peroxisome Proliferator-Activated Receptor Beta/Delta Agonists: Avoiding False Positives.

Videira NB, Batista FAH, Torres Cordeiro A, Figueira ACM.

PPAR Res. 2018 Apr 12;2018:3681590. doi: 10.1155/2018/3681590. eCollection 2018.

13.

The Hepatoprotection by Oleanolic Acid Preconditioning: Focusing on PPARα Activation.

Wang W, Chen K, Xia Y, Mo W, Wang F, Dai W, Niu P.

PPAR Res. 2018 Apr 2;2018:3180396. doi: 10.1155/2018/3180396. eCollection 2018.

14.

Treatment of Diabetic Mice with a Combination of Ketogenic Diet and Aerobic Exercise via Modulations of PPARs Gene Programs.

Zhang Q, Xu L, Xia J, Wang D, Qian M, Ding S.

PPAR Res. 2018 Mar 20;2018:4827643. doi: 10.1155/2018/4827643. eCollection 2018.

15.

High Glucose Induces Autophagy through PPARγ-Dependent Pathway in Human Nucleus Pulposus Cells.

Jiang C, Liu S, Cao Y, Shan H.

PPAR Res. 2018 Mar 1;2018:8512745. doi: 10.1155/2018/8512745. eCollection 2018.

16.

PPARγ Antagonizes Hypoxia-Induced Activation of Hepatic Stellate Cell through Cross Mediating PI3K/AKT and cGMP/PKG Signaling.

Zhang Q, Xiang S, Liu Q, Gu T, Yao Y, Lu X.

PPAR Res. 2018 Mar 1;2018:6970407. doi: 10.1155/2018/6970407. eCollection 2018.

17.

Peroxisome Proliferator-Activated Receptor γ and PGC-1α in Cancer: Dual Actions as Tumor Promoter and Suppressor.

Yun SH, Han SH, Park JI.

PPAR Res. 2018 Jan 21;2018:6727421. doi: 10.1155/2018/6727421. eCollection 2018. Review.

18.

Vascular Remodeling, Oxidative Stress, and Disrupted PPARγ Expression in Rats of Long-Term Hyperhomocysteinemia with Metabolic Disturbance.

Huo Y, Wu X, Ding J, Geng Y, Qiao W, Ge A, Guo C, Lv J, Bao H, Fan W.

PPAR Res. 2018 Jan 15;2018:6738703. doi: 10.1155/2018/6738703. eCollection 2018.

19.

Portulaca Extract Attenuates Development of Dextran Sulfate Sodium Induced Colitis in Mice through Activation of PPARγ.

Kong R, Luo H, Wang N, Li J, Xu S, Chen K, Feng J, Wu L, Li S, Liu T, Lu X, Xia Y, Shi Y, Zhou Y, He W, Dai Q, Zheng Y, Lu J.

PPAR Res. 2018 Feb 1;2018:6079101. doi: 10.1155/2018/6079101. eCollection 2018.

20.

Research Advances in the Correlation between Peroxisome Proliferator-Activated Receptor-γ and Digestive Cancers.

Xu S, Xu X.

PPAR Res. 2018 Feb 1;2018:5289859. doi: 10.1155/2018/5289859. eCollection 2018. Review.

Supplemental Content

Loading ...
Support Center